Want to see AU:PAR full AI Analyst Report?
Top Page
Paradigm Biopharmaceuticals
(Sydney:PAR)
Select Model
Select Model
Rating:43Neutral
Price Target:
AU$0.15
▼(-9.38% Downside)
Action:Reiterated
Date:04/30/26
The score is primarily constrained by weak financial performance (minimal revenue, persistent losses, and ongoing cash burn despite improvement) and bearish technical conditions (price below key moving averages with negative MACD). Valuation contributes little support because the company is loss-making (negative P/E) and no dividend yield is provided.
Positive Factors
Low leverage
A conservatively levered balance sheet reduces refinancing and interest-rate risk for a cash-burning biotech. Low debt preserves capacity to raise capital via equity or partnerships, supporting long-term investment in trials, approvals and commercialization without immediate solvency pressure.
Negative Factors
Persistent negative cash flow
Ongoing negative operating and free cash flow indicates the business cannot self-fund operations or growth. Reliance on external capital is likely to persist, increasing dilution risk and constraining long-term R&D, regulatory and commercial investments if funding conditions tighten.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
A conservatively levered balance sheet reduces refinancing and interest-rate risk for a cash-burning biotech. Low debt preserves capacity to raise capital via equity or partnerships, supporting long-term investment in trials, approvals and commercialization without immediate solvency pressure.
Read all positive factors
Paradigm Biopharmaceuticals (PAR) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$107.85M
Dividend YieldN/A
Average Volume (3M)841.61K
Price to Earnings (P/E)―
Beta (1Y)2.38
Revenue Growth-26.58%
EPS Growth-100.90%
CountryAU
Employees12
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.09
Shares Outstanding599,189,900
10 Day Avg. Volume720,106
30 Day Avg. Volume841,610
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)4.53
Price to Sales (P/S)1840.42
P/FCF Ratio-6.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.42Price Target Upside162.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.09
Revenue Forecast (FY)N/A
Paradigm Biopharmaceuticals Business Overview & Revenue Model
Company Description
Based in Melbourne, Australia, Paradigm Biopharmaceuticals Limited specializes in the repurposing of existing drugs, developing therapeutic solutions for human health. A central offering is an injectable formulation of pentosan polysulfate sodium,...
How the Company Makes Money
null...
Paradigm Biopharmaceuticals Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
66
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 60.57K | 52.12K | 65.80K | 46.76K | 79.22K | 20.55K |
| Gross Profit | -97.57K | -19.89K | 56.81K | -18.83K | -64.53K | -78.59K |
| EBITDA | -40.72M | -25.25M | -64.54M | -59.06M | -46.82M | -42.40M |
| Net Income | -36.09M | -18.77M | -58.65M | -51.91M | -39.25M | -34.30M |
Balance Sheet | ||||||
| Total Assets | 23.15M | 24.57M | 27.39M | 67.07M | 50.69M | 84.79M |
| Cash, Cash Equivalents and Short-Term Investments | 14.66M | 16.82M | 17.87M | 56.38M | 39.72M | 71.08M |
| Total Debt | 1.01M | 5.48K | 239.33K | 341.67K | 616.67K | 751.84K |
| Total Liabilities | 17.16M | 3.39M | 3.58M | 13.39M | 8.38M | 6.52M |
| Stockholders Equity | 6.00M | 21.18M | 23.81M | 53.68M | 42.31M | 78.27M |
Cash Flow | ||||||
| Free Cash Flow | -7.77M | -15.99M | -65.94M | -45.19M | -32.21M | -34.96M |
| Operating Cash Flow | -27.42M | -15.99M | -65.94M | -45.19M | -32.21M | -34.93M |
| Investing Cash Flow | -567.20K | 46.20K | 0.00 | 0.00 | 0.00 | 668.37K |
| Financing Cash Flow | 18.17M | 14.99M | 28.18M | 62.53M | 70.12K | 1.00M |
Paradigm Biopharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$177.12M | -10.85 | -278.87% | ― | 1219.92% | 38.88% | |
50 Neutral | AU$169.23M | -7.84 | -134.14% | ― | ― | -70.59% | |
48 Neutral | AU$60.21M | -0.47 | -131.13% | ― | 2086.71% | -116.20% | |
43 Neutral | AU$107.85M | -2.02 | -265.55% | ― | -26.58% | -100.90% | |
43 Neutral | AU$74.43M | -8.68 | -18.71% | ― | ― | 21.23% | |
41 Neutral | AU$113.13M | -3.27 | 279.21% | ― | ― | -37.23% |
* Healthcare Sector Average
AU:PAR
Paradigm Biopharmaceuticals
0.18
-0.14
-42.86%
AU:ATX
Amplia Therapeutics
0.15
-0.06
-27.50%
AU:ACW
Actinogen Medical
0.05
0.02
73.08%
AU:DXB
Dimerix Limited
0.30
-0.17
-35.87%
AU:BOT
Botanix Pharmaceuticals Limited
0.02
-0.13
-85.33%
AU:RCE
Recce Pharmaceuticals Ltd.
0.37
-0.04
-10.84%
Paradigm Biopharmaceuticals Corporate Events
Paradigm Biopharmaceuticals Cancels Shares Under Employee Scheme Buy-Back
Jul 26, 2026
Paradigm Biopharmaceuticals has updated the market on changes to its issued capital, notifying the cessation of 300,000 ordinary fully paid shares. The shares were cancelled as a result of an employee share scheme buy-back, reflecting routine capi...
Paradigm gains $5.75m tax-related cash boost to fund Phase 3 osteoarthritis program
Jul 21, 2026
Paradigm Biopharmaceuticals has received a combined $5.75 million in cash through Australia’s Research Development Tax Incentive for FY25 and an amended FY23 income tax refund, bolstering its balance sheet. The additional funding supports t...
Paradigm Biopharmaceuticals issues cleansing notice for latest US$3m convertible notes
Jul 13, 2026
Paradigm Biopharmaceuticals has issued a cleansing notice covering a new tranche of US$3 million in convertible notes, termed the July 2026 Notes, under its existing convertible securities and share placement agreement with Obsidian Global GP LLC....
Paradigm Biopharmaceuticals Issues 3 Million Unquoted Convertible Notes
Jul 13, 2026
Paradigm Biopharmaceuticals has notified the market of the issuance of 3,000,000 unquoted convertible notes under the ASX Appendix 3G framework. The notes, recorded with the security code PARAAD and issued on July 13, 2026, form part of a previous...
Paradigm Secures Fresh Funds to Advance Phase 3 Knee Osteoarthritis Trial
Jul 13, 2026
Paradigm Biopharmaceuticals has drawn down Tranche 4 of its US$27 million convertible note facility with Obsidian Global Partners, securing an additional US$3 million in working capital. The funds will support the ongoing global Phase 3 clinical t...
Paradigm Biopharmaceuticals updates market on director’s shareholding change
Jul 1, 2026
Paradigm Biopharmaceuticals has disclosed a change in director Paul Rennie’s relevant interests in the company’s securities, as required under ASX listing rules. The notice details his mix of direct and indirect holdings, including ful...
Paradigm Biopharmaceuticals Cancels 939,500 Lapsed Performance Rights
Jun 29, 2026
Paradigm Biopharmaceuticals has reported the lapse of 939,500 performance rights, identified under the ASX security code PARAAC, after the conditions attached to these rights were not met or became incapable of being satisfied. The cessation of th...
Paradigm Biopharmaceuticals Cancels Shares Under Employee Scheme Buy-Back
Jun 29, 2026
Paradigm Biopharmaceuticals has cancelled 1,795,000 ordinary fully paid shares as part of an employee share scheme buy-back, effective June 29, 2026. The reduction in issued capital reflects the company’s ongoing management of its equity str...
Paradigm Biopharmaceuticals Updates Director Matthew Fry’s Option Holdings
Jun 18, 2026
Paradigm Biopharmaceuticals has disclosed a change in the indirect interests of director Matthew Fry, who has been issued 176,470 listed options at an exercise price of $0.2375, expiring on December 1, 2026, under an options offer. Following this ...
Paradigm Biopharmaceuticals updates market on director Paul Rennie’s expanded option holdings
Jun 18, 2026
Paradigm Biopharmaceuticals has reported a change in the interests of director Paul Rennie, reflecting adjustments across his direct and indirect holdings in the company’s securities. The disclosure details his mix of fully paid ordinary sha...
Paradigm Biopharmaceuticals Seeks ASX Quotation for Over 10 Million New Shares
Jun 18, 2026
Paradigm Biopharmaceuticals has applied for the quotation of 10,139,313 new ordinary fully paid shares on the Australian Securities Exchange. The newly issued securities, dated June 18, 2026, expand the company’s quoted share capital, which ...
Paradigm Biopharmaceuticals’ Top 20 Option Holders Control Majority of PAROPTWC Register
Jun 17, 2026
Paradigm Biopharmaceuticals has released an updated top holders report for its listed options expiring 1 December 2026, priced at $0.2375, revealing that the top 20 holders control 57.78% of the 117,069,101 options on issue. Major custodians and n...
Paradigm Biopharmaceuticals Seeks ASX Quotation for 117 Million New Options
Jun 17, 2026
Paradigm Biopharmaceuticals has applied to the ASX for quotation of a new class of options, expanding its listed securities and broadening its capital structure. The company plans to list 117,069,101 options expiring on 1 December 2026 or 20 busin...
Paradigm Director Increases Stake via Share Purchase Plan
Jun 5, 2026
Paradigm Biopharmaceuticals has disclosed a change in director Matthew Fry’s indirect shareholding following his participation in a share purchase plan. Fry acquired 176,470 fully paid ordinary shares for $30,000, increasing his indirect hol...
Paradigm Director Paul Rennie Increases Stake Through Additional Share Purchases
Jun 5, 2026
Paradigm Biopharmaceuticals has announced changes to the interests of director Paul Rennie in the company’s securities, following a recent on-market acquisition. Rennie increased his holdings across several direct and indirect accounts, incl...
Paradigm Biopharmaceuticals Redeems Over 1.3 Million Convertible Notes
Jun 3, 2026
Paradigm Biopharmaceuticals Limited has announced the cessation of 1,352,815 convertible notes, identified under the ASX code PARAAD, following their repayment or redemption without conversion into equity. The cessation, effective 3 June 2026, red...
Paradigm Biopharmaceuticals Seeks Quotation for 7.7 Million New Shares on ASX
Jun 2, 2026
Paradigm Biopharmaceuticals has applied for quotation on the ASX of 7,657,720 new fully paid ordinary shares, following the exercise or conversion of existing options or other convertible securities. The admission of these additional shares to tra...
Paradigm Biopharmaceuticals Seeks ASX Quotation for 43.4 Million New Shares
Jun 2, 2026
Paradigm Biopharmaceuticals has applied for quotation on the ASX of 43,384,890 new ordinary fully paid shares, effective 2 June 2026. The move increases the number of tradable securities on issue and may enhance liquidity in Paradigm’s stock...
Paradigm Biopharmaceuticals Corrects Share Purchase Plan Details in ASX Filing
Jun 1, 2026
Paradigm Biopharmaceuticals has updated its disclosure to the ASX regarding a proposed issue of securities under its share purchase plan, correcting the final number of shares to be issued on completion. The company also confirmed there will be no...
Paradigm Secures $21.35m After Oversubscribed Share Purchase Plan
Jun 1, 2026
Paradigm Biopharmaceuticals has completed an oversubscribed Share Purchase Plan that raised about $7.375 million from existing shareholders at $0.17 per share, well above the original $2 million target. Together with a recently completed $14 milli...
Paradigm Biopharmaceuticals sets June in‑person shareholder meeting with digital proxy push
May 12, 2026
Paradigm Biopharmaceuticals has called a General Meeting of shareholders to be held in person at its Melbourne offices on 11 June 2026, underscoring the company’s continued reliance on formal in‑person governance forums. The notice of ...
Paradigm Completes Institutional Placement and Prepares Share Purchase Plan
Apr 30, 2026
Paradigm Biopharmaceuticals has completed a placement of 73,684,211 fully paid ordinary shares at $0.19 per share to institutional and sophisticated investors, raising new equity capital without a prospectus under Australian Corporations Act provi...
Paradigm Biopharmaceuticals Seeks Quotation for 73.7 Million New Shares on ASX
Apr 30, 2026
Paradigm Biopharmaceuticals has applied for quotation on the ASX of 73,684,211 new fully paid ordinary shares, to be issued on 1 May 2026. The move expands the company’s quoted share base and may support future capital needs, potentially enh...
Paradigm Reshapes Obsidian Funding Terms Around Phase 3 Milestones
Apr 30, 2026
Paradigm Biopharmaceuticals has amended its convertible securities and share placement agreement with Obsidian Global GP, LLC, tying future drawdowns to clinical and shareholder milestones while using part of its recent capital raising to repay ex...
Paradigm Biopharmaceuticals Launches $2m Share Purchase Plan After $14m Placement
Apr 30, 2026
Paradigm Biopharmaceuticals has completed a $14 million placement of 73,684,211 new shares at $0.19 each, with investors also receiving free-attaching options that include additional piggyback options upon exercise. The company is now offering eli...
Paradigm Clears Key Safety Milestone and Expands Sites in Phase 3 Osteoarthritis Trial
Apr 29, 2026
Paradigm Biopharmaceuticals said its pivotal Phase 3 PARA_OA_012 trial of injectable pentosan polysulfate sodium for knee osteoarthritis will continue as planned after an independent Data Safety Monitoring Board completed a scheduled review of saf...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.